title: Antibiotic treatment of experimentally Borrelia burgdorferi-infected ponies.
abstract: The objective of this study is to determine whether doxycycline, ceftiofur or tetracycline could be effectively used to treat equine Lyme disease. Ponies experimentally infected with Borrelia burgdorferi by tick exposure were treated with doxycycline, ceftiofur or tetracycline for 4 weeks (28 days). Doxycyline and ceftiofur treatment were inconsistent in eliminating persistent infection in this experimental model. However, tetracycline treatment seems to eliminate persistent infection. Although serum antibody levels to B. burgdorferi in all ponies declined gradually after antibiotic treatment, three out of four ponies treated with doxycline and two out of four ponies treated with ceftiofur, serum KELA titers were raised again 3 month after treatment was discontinued. Five months after antibiotic treatment, tissues aseptically collected at necropsy from ponies with increased antibody levels after antibiotic treatment also showed culture positive to B. burgdorferi in various post-mortem tissues. However, all four-tetracycline treatment ponies showed a negative antibody level and culture negative from post-mortem tissues. Untreated infected ponies maintained high KELA titers throughout the study and were tissue culture positive.
authors.affiliation: College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA. yc42@cornell.edu
authors.forename: Yung-Fu
authors.initials: YF
authors.lastname: Chang
authors.forename: Yu-We
authors.initials: YW
authors.lastname: Ku
authors.forename: Chao-Fu
authors.initials: CF
authors.lastname: Chang
authors.forename: Ching-Dong
authors.initials: CD
authors.lastname: Chang
authors.forename: Sean P
authors.initials: SP
authors.lastname: McDonough
authors.forename: Thomas
authors.initials: T
authors.lastname: Divers
authors.forename: Margaret
authors.initials: M
authors.lastname: Pough
authors.forename: Alfonso
authors.initials: A
authors.lastname: Torres
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000907:Antibodies, Bacterial / Q000097:blood; D001706:Biopsy / Q000662:veterinary; D015153:Blotting, Western / Q000662:veterinary; D025065:Borrelia burgdorferi / Q000235:genetics / Q000254:growth & development*; D002511:Cephalosporins / Q000627:therapeutic use; D004269:DNA, Bacterial / Q000737:chemistry / Q000235:genetics; D004318:Doxycycline / Q000627:therapeutic use; D004797:Enzyme-Linked Immunosorbent Assay / Q000662:veterinary; D005260:Female; D006651:Histocytochemistry / Q000662:veterinary; D006734:Horse Diseases / Q000188:drug therapy* / Q000382:microbiology* / Q000635:transmission; D006736:Horses; D018884:Ixodes / Q000382:microbiology; D008193:Lyme Disease / Q000188:drug therapy* / Q000382:microbiology / Q000635:transmission / Q000662:veterinary*; D008297:Male; D016133:Polymerase Chain Reaction / Q000662:veterinary; D013752:Tetracycline / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; D002511:Cephalosporins; D004269:DNA, Bacterial; C053503:ceftiofur; D013752:Tetracycline; D004318:Doxycycline